RetinalGeniX Technologies Inc. Appoints Dessy Boneva, M.D. to Board of Directors
PETALUMA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) — RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”) has recently announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors. This strategic appointment comes as RetinalGeniX continues to make waves in the ophthalmic research and development industry with their focus on High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies.
A Visionary Addition to the Team
Dr. Boneva brings a wealth of experience and expertise to RetinalGeniX Technologies Inc. With a background in ophthalmology and a strong passion for advancing healthcare technologies, she is well-positioned to drive the company’s mission forward. Her innovative approach and strategic vision make her a valuable addition to the Board of Directors.
Revolutionizing Retinal Imaging and Drug Development
RetinalGeniX is at the forefront of revolutionizing retinal imaging and drug development. Their High-Resolution Retinal Imaging technology provides detailed insights into retinal health, allowing for early detection and precise monitoring of various eye conditions. Pharmaco-Genetic Mapping™ technology, on the other hand, enables personalized treatment approaches based on individual genetic profiles.
By combining these cutting-edge technologies, RetinalGeniX is paving the way for more effective and personalized healthcare solutions in the field of ophthalmology.
Impact on Individuals
For individuals, the advancements made by RetinalGeniX Technologies Inc. mean improved access to early detection and personalized treatment options for various eye conditions. By leveraging High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies, patients can benefit from more accurate diagnoses and tailored treatment plans, ultimately leading to better outcomes and quality of life.
Global Implications
On a global scale, RetinalGeniX’s innovative technologies have the potential to revolutionize the way eye health is approached and managed worldwide. By providing healthcare professionals with advanced tools for diagnosis and treatment, the company is contributing to the global effort to improve healthcare outcomes and enhance patient care.
Conclusion
The appointment of Dr. Dessy Boneva to the Board of Directors at RetinalGeniX Technologies Inc. marks a significant milestone in the company’s journey towards advancing ophthalmic research and development. With a focus on High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies, RetinalGeniX is poised to make a lasting impact on the field of eye health, both at an individual level and on a global scale. The future looks bright for RetinalGeniX and the innovative solutions they are bringing to the healthcare industry.
